Company news
Neumora Therapeutics, Inc. (NASDAQ:NMRA) news
Every Neumora Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
July 27, 2026
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
June 15, 2026
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
March 16, 2026
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
January 5, 2026
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
January 5, 2026
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
November 3, 2025
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
October 27, 2025
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
October 27, 2025
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
October 27, 2025
Neumora Therapeutics to Host Virtual R&D Day on October 27
October 1, 2025
Neumora Therapeutics to Participate in Upcoming Conferences in September
September 2, 2025
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
July 23, 2025
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
July 9, 2025
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
April 28, 2025
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
March 4, 2025
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 3, 2025
Neumora Therapeutics Announces Leadership Transition
February 13, 2025
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
January 2, 2025
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 29, 2024
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
August 14, 2024
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 6, 2024
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
June 20, 2024
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
May 14, 2024
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 6, 2024
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 15, 2024
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 13, 2024
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 7, 2024
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 22, 2024
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
December 12, 2023
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
November 27, 2023
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 1, 2023
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
October 10, 2023